Skip to main content
Top
Published in: Diabetologia 8/2012

01-08-2012 | Short Communication

HbA1c variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2

Authors: A. Sugawara, K. Kawai, S. Motohashi, K. Saito, S. Kodama, Y. Yachi, R. Hirasawa, H. Shimano, K. Yamazaki, H. Sone

Published in: Diabetologia | Issue 8/2012

Login to get access

Abstract

Aims/hypothesis

The aim of this study was to examine the association between HbA1c variability and the development of microalbuminuria as defined by an albumin/creatinine ratio ≥3.4 mg/mmol (≥30 mg/g) in at least two of three consecutive urine samples in Japanese patients with type 2 diabetes.

Methods

HbA1c level was measured in 812 serially registered normoalbuminuric adults aged 21–79 years with type 2 diabetes. After registration, a 1-year period to establish baseline values for mean HbA1c and HbA1c variability (measured as the intrapersonal SD of serially collected HbA1c) was decided upon. The association between HbA1c variability and the development of microalbuminuria was determined by Cox regression analysis after adjustment for other risk factors for microalbuminuria.

Results

Microalbuminuria occurred in 193 patients during the observation period of (mean ± SD) 4.3 ± 2.7 years. Even after adjustment for mean HbA1c, HbA1c variability was a significant predictor of microalbuminuria independently of the mean HbA1c; the HR for every 1% (95% CI) increase in mean HbA1c was 1.22 (1.06, 1.40) (p = 0.005), and that for HbA1c variability was 1.35 (1.05, 1.72) (p = 0.019). The effects of these two variables were quite similar when 1 SD was used; the HR for every 1 SD increase (95% CI) in HbA1c was 1.23 (1.07, 1.43) (p = 0.005), and that for HbA1c variability was 1.20 (1.03, 1.39) (p = 0.019).

Conclusions/interpretation

HbA1c variability affects the development of microalbuminuria independently of mean HbA1c in type 2 diabetes. Further studies should be performed to evaluate the influence of HbA1c variability on other complications and in individuals of other ethnicities with type 2 diabetes.
Literature
1.
go back to reference UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837–853CrossRef UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837–853CrossRef
2.
go back to reference Kilpatrick ES, Rigby AS, Atkin SL (2008) A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 31:2198–2202PubMedCrossRef Kilpatrick ES, Rigby AS, Atkin SL (2008) A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 31:2198–2202PubMedCrossRef
3.
go back to reference Waden J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH (2009) A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 58:2649–2655PubMedCrossRef Waden J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH (2009) A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 58:2649–2655PubMedCrossRef
4.
go back to reference Sone H, Mizuno S, Yamada N (2005) Vascular risk factors and diabetic neuropathy. N Engl J Med 352:1925–1927, author reply 1925–1927PubMedCrossRef Sone H, Mizuno S, Yamada N (2005) Vascular risk factors and diabetic neuropathy. N Engl J Med 352:1925–1927, author reply 1925–1927PubMedCrossRef
5.
go back to reference Saito K, Sone H, Kawai K et al (2007) Risk imparted by various parameters of smoking in Japanese men with type 2 diabetes on their development of microalbuminuria: analysis from the Tsukuba Kawai Diabetes Registry. Diabetes Care 30:1286–1288PubMedCrossRef Saito K, Sone H, Kawai K et al (2007) Risk imparted by various parameters of smoking in Japanese men with type 2 diabetes on their development of microalbuminuria: analysis from the Tsukuba Kawai Diabetes Registry. Diabetes Care 30:1286–1288PubMedCrossRef
6.
go back to reference The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus (2010) Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Japan Diab Soc 53:450–467 The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus (2010) Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Japan Diab Soc 53:450–467
7.
go back to reference Kim CS, Park SY, Yu SH et al (2010) Is A1C variability an independent predictor for the progression of atherosclerosis in type 2 diabetic patients? Korean Diabetes J 34:174–181PubMedCrossRef Kim CS, Park SY, Yu SH et al (2010) Is A1C variability an independent predictor for the progression of atherosclerosis in type 2 diabetic patients? Korean Diabetes J 34:174–181PubMedCrossRef
8.
go back to reference Marcovecchio ML, Dalton RN, Chiarelli F, Dunger DB (2011) A1C variability as an independent risk factor for microalbuminuria in young people with type 1 diabetes. Diabetes Care 34:1011–1013PubMedCrossRef Marcovecchio ML, Dalton RN, Chiarelli F, Dunger DB (2011) A1C variability as an independent risk factor for microalbuminuria in young people with type 1 diabetes. Diabetes Care 34:1011–1013PubMedCrossRef
9.
go back to reference Monnier L, Mas E, Ginet C et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681–1687PubMedCrossRef Monnier L, Mas E, Ginet C et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681–1687PubMedCrossRef
10.
go back to reference Katayama S, Moriya T, Tanaka S et al (2011) Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS). Diabetologia 54:1025–1031PubMedCrossRef Katayama S, Moriya T, Tanaka S et al (2011) Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS). Diabetologia 54:1025–1031PubMedCrossRef
Metadata
Title
HbA1c variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2
Authors
A. Sugawara
K. Kawai
S. Motohashi
K. Saito
S. Kodama
Y. Yachi
R. Hirasawa
H. Shimano
K. Yamazaki
H. Sone
Publication date
01-08-2012
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2572-7

Other articles of this Issue 8/2012

Diabetologia 8/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.